Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's complete response letter for deutetrabenazine for treatment of chorea associated Huntington disease does not request additional clinical trials, and Teva said a filing timeline for tardive dyskinesia remains unchanged.
You may also be interested in...
Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.
Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Neurocrine submits NDA for its VMAT inhibitor valbenazine for tardive dyskinesia, getting to FDA ahead of Teva, which is developing a similar product, deutetrabenazine, for the same indication.